Bionano Interactions of Organosilica Nanoparticles with Myeloid Derived Immune Cells

Edward Henderson, Kirsty Wilson, Gabriel Huynh, Magdalena Plebanski, Simon Corrie

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Investigating the interactions between nanomaterials and the cells they are likely to encounter in vivo is a critical aspect of designing nanomedicines for imaging and therapeutic applications. Immune cells such as dendritic cells, macrophages, and myeloid derived suppressor cells have a frontline role in the identification and removal of foreign materials from the body, with interactions shown to be heavily dependent on variables such as nanoparticle size, charge, and surface chemistry. Interactions such as cellular association or uptake of nanoparticles can lead to diminished functionality or rapid clearance from the body, making it critical to consider these interactions when designing and synthesizing nanomaterials for biomedical applications ranging from drug delivery to imaging and biosensing. We investigated the interactions between PEGylated organosilica nanoparticles and naturally endocytic immune cells grown from stem cells in murine bone marrow. Specifically, we varied the particle size from 60 nm up to 1000 nm and investigated the effects of size on immune cell association, activation, and maturation with these critical gatekeeper cells. These results will help inform future design parameters for in vitro and in vivo biomedical applications utilizing organosilica nanoparticles.

Original languageEnglish
Pages (from-to)43329-43340
Number of pages12
JournalACS Applied Materials and Interfaces
Volume16
Issue number33
DOIs
Publication statusPublished - 7 Aug 2024

Keywords

  • association
  • immune activation
  • nanoparticle size
  • nanoparticles
  • organosilica
  • stem cell culture
  • uptake
  • ARC Training Centre for Cell and Tissue Engineering Technologies

    Meagher, L. (Primary Chief Investigator (PCI)), Bray, L. J. (Chief Investigator (CI)), Voelcker, N. (Chief Investigator (CI)), Risbridger, G. (Chief Investigator (CI)), Hutmacher, D. W. (Chief Investigator (CI)), Batra, J. (Chief Investigator (CI)), Dargaville, T. (Chief Investigator (CI)), Elnathan, R. (Chief Investigator (CI)), Saifzadeh, S. (Chief Investigator (CI)), Heng, T. (Chief Investigator (CI)), Aguilar, M. (Chief Investigator (CI)), Lim, R. (Partner Investigator (PI)), Klein, T. J. (Chief Investigator (CI)), Fisher, A. (Partner Investigator (PI)), McGovern, J. (Chief Investigator (CI)), Dislakis, V. (Partner Investigator (PI)), McLellan, A. (Partner Investigator (PI)), Dulleck, U. (Chief Investigator (CI)), Steck, R. (Chief Investigator (CI)), Scott, W. (Partner Investigator (PI)), Corrie, S. (Chief Investigator (CI)), Thissen, H. (Partner Investigator (PI)), Cameron, N. (Chief Investigator (CI)), Haupt, L. (Chief Investigator (CI)), Werner, C. (Partner Investigator (PI)), Levett, P. (Partner Investigator (PI)), Whyte, S. (Chief Investigator (CI)), Forsythe, J. (Chief Investigator (CI)), Smith, N. (Partner Investigator (PI)), Frith, J. (Chief Investigator (CI)), Hicks, C. (Partner Investigator (PI)), Rackham, O. J. L. (Partner Investigator (PI)), Sohal, A. (Chief Investigator (CI)), Polo, J. (Chief Investigator (CI)), May, M. (Partner Investigator (PI)), Reimers, N. (Partner Investigator (PI)), Toh, Y.-C. (Chief Investigator (CI)), McKee, J. (Partner Investigator (PI)), Adams, M. (Chief Investigator (CI)), Obschonka, M. (Partner Investigator (PI)), Subramaniam, N. (Chief Investigator (CI)), Yambem, S. D. (Chief Investigator (CI)), Russell-Bennett, R. (Chief Investigator (CI)), Bertram, J. (Chief Investigator (CI)), Schierjott, R. (Partner Investigator (PI)), Hollands, J. (Partner Investigator (PI)), Currie, P. (Chief Investigator (CI)), Ball, G. (Partner Investigator (PI)), Trapani, J. A. (Partner Investigator (PI)), Cadarso Busto, V. (Chief Investigator (CI)), Loessner, D. (Chief Investigator (CI)), Ecker, R. (Partner Investigator (PI)), Boyd, R. L. (Partner Investigator (PI)) & Lim, J. (Partner Investigator (PI))

    Australian Research Council (ARC), PolVax Pty Ltd, Cartherics Pty Ltd, TissueGUARD GmbH, Peter MacCallum Cancer Centre, TissueGnostics GmbH

    13/01/2130/11/27

    Project: Research

Cite this